{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["eprenetapopt","azacitidine"]],"indication":"TP53-mutant AML or MDS following allogeneic stem-cell transplant","name":"NCT03931291","nct_id":"NCT03931291","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct03931291. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"APR-246 and azacitidine maintenance therapy will continue for a maximum of 12 cycles","label":"Experimental arm: APR-246 + azacitidine","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2022-01-14","type":"ACTUAL"},"conditions":["Acute Myeloid Leukemia or Myelodysplastic Syndromes"],"enrollment":{"count":33,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"APR-246","otherNames":["Azacitidine"],"type":"DRUG"}],"last_update":"2025-03-17","lead_sponsor":"Aprea Therapeutics","official_title":"Phase II Trial of APR-246 in Combination With Azacitidine as Maintenance Therapy for TP53 Mutated AML or MDS Following Allogeneic Stem Cell Transplant","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2021-08-27","type":"ACTUAL"},"primary_outcomes":[{"measure":"To Assess Relapse-free Survival (RFS) in Patients With TP53 Mutated AML or MDS After Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HSCT).","timeFrame":"Through study completion, an average of 1 year"}],"references":[{"citation":"Mishra A, Tamari R, DeZern AE, Byrne MT, Gooptu M, Chen YB, Deeg HJ, Sallman D, Gallacher P, Wennborg A, Hickman DK, Attar EC, Fernandez HF. Eprenetapopt Plus Azacitidine After Allogeneic Hematopoietic Stem-Cell Transplantation for TP53-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes. J Clin Oncol. 2022 Dec 1;40(34):3985-3993. doi: 10.1200/JCO.22.00181. Epub 2022 Jul 11.","pmid":"35816664","type":"DERIVED"}],"start_date":{"date":"2019-09-16","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant","url":"https://clinicaltrials.gov/study/NCT03931291"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct03931291"}